A phase 2 trial performed in 18 centers in France enrolled 3 patients with RMC and reported no benefit from the addition of bevacizumab to platinum-based chemotherapy with gemcitabine + platinum. Despite the low numbers of patients with RMC enrolled, the lack of bevacizumab is consistent with prior clinical experience and the emerging mechanistic understanding that the loss of SMARCB1 loss protects RMC from VEGF inhibition.